REIN

Ramipril Efficacy in Nephropathy

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 352 patients with non-diabetic proteinuric chronic kidney disease, ramipril slowed GFR decline and progression to ESRD compared with placebo.

166

Schéma

RCT (stratum with proteinuria ≥3 g/day)

Critère

Rate of GFR decline; progression to ESRD

Pertinence

RésultatGFR decline 0.53 vs 0.88 mL/min/month (p=0.03); doubling of creatinine or ESRD in 18 (ramipril) vs 40 (placebo), p=0.04.

GISEN Group. Lancet. 1997;349(9069):1857-1863. 10.1016/S0140-6736(96)11445-8

Discussion et critique

Extended ACE-inhibitor renoprotection to non-diabetic proteinuric CKD; basis for a 1A guideline recommendation.